TellRx Platform

About TellBio

TellBio is a private, development-stage biotech leveraging a proprietary microfluidic platform to isolate and analyze circulating tumor cells (CTCs), licensed from Massachusetts General Hospital. Its core diagnostic system, TellDx, is deployed as a research tool globally, with data informing a complementary therapeutic pipeline, TellRx. The company aims to address critical unmet needs in early cancer detection, monitoring metastasis, and developing targeted therapies, positioning itself as a revenue-generating entity through its research tools while advancing toward clinical applications.

Therapeutic Areas

Other Metastatic Cancer Drugs